The Quebec government has released its provincial Rare Disease Policy. This is the first jurisdiction in Canada to develop a policy for rare diseases that aims to help patients suffering from a rare disease gain better access to diagnosis, health care and treatment.

The PMPRB has responded to the statement made April 14, 2022, by the Federal Minister of Health, Minister Duclos regarding the Coming-into-Force of the Regulations Amending the Patented Medicines Regulations.

On March 24, 2022, the Supreme Court of Canada dismissed the application by the Attorney General of Canada in its appeal to the Federal Court Decision in the SOLIRIS case.

The Quebec Court of Appeal has confirmed that is it unconstitutional for the PMPRB to compel companies to provide information from 3rd party agreements.

On December 23, 2021, the Minister of Health, Jean-Yves Duclos announced a delay in the coming-into-force of the Regulations Amending the Patented Medicines Regulations by six months.

On December 17, 2021, the PMPRB posted an update that read, “The Board has decided not to proceed with the changes that were proposed in the July 15, 2021 Notice and Comment.

Read about the two major announcements have been made in the last couple of weeks pertaining to the PMPRB.

CADTH has announced the establishment of a Special Advisory Panel to design a potential pan-Canadian formulary.

The PMPRB has updated their website to state the coming-into-force of the amended Patented Medicines Regulations has been further delayed until January 1, 2022.

Twitter was abuzz with a letter from Christopher MacLeod, Canadian Cystic Fibrosis Treatment Society to the President of the Treasury Board, House of Commons & the Auditor General Canada with a request to investigate PMPRB for “targeting & de-legitimizing the Patient Voice”.